Beam Therapeutics' BEAM-101 Shows Promising Results in Sickle Cell Disease Trial

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best CRISPR stocks to buy. On June 13, Beam Therapeutics Inc. (NASDAQ:BEAM) announced new efficacy and safety findings from its BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) patients experiencing acute vaso-occlusive crises.

As first established in previously released data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2024, the strong clinical profile for BEAM-101 is reinforced by the new data from the BEACON trial, which has more patients and a longer follow-up.

BEAM-101 revealed fast neutrophil and platelet engraftment, normalized or enhanced hemolysis and oxygen delivery parameters, and significant increases in fetal hemoglobin (HbF) along with decreases in sickle hemoglobin (HbS) in 17 patients. Speaking on these results, Ashish Gupta, associate professor at the University of Minnesota and an investigator in the BEACON trial, stated the following:

“Given this profile, BEAM-101 has the potential to further restore red blood cell health and function, reduce hospital time for patients, and decrease the overall burden of cell and gene therapy treatment for patients and providers.”

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company that employs its in-house base-editing technology to lead the way in precision genetic medicine. In contrast to conventional CRISPR treatments, the company’s primary focus is on creating long-lasting cures for serious illnesses, such as certain forms of blood cancer.

While we acknowledge the potential of BEAM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.